The stock of Netscientific PLC (LON:NSCI) hit a new 52-week low and has GBX 52.80 target or 12.00% below today’s GBX 60.00 share price. The 7 months bearish chart indicates high risk for the GBX 30.41M company. The 1-year low was reported on Nov, 9 by Barchart.com. If the GBX 52.80 price target is reached, the company will be worth GBX 3.65M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 8.40% or GBX 5.5 on November 9, hitting GBX 60. About 2,500 shares traded hands. Netscientific PLC (LON:NSCI) has declined 12.08% since April 8, 2016 and is downtrending. It has underperformed by 16.86% the S&P500.
More important recent Netscientific PLC (LON:NSCI) news were published by: Businesswire.com which released: “NetScientific plc: Ex Novartis Diagnostics president, Gene Walther is …” on December 14, 2015, also Fool.Co.Uk published article titled: “Is Netscientific PLC A Better Buy Than Smith & Nephew plc And Dechra …”, Businesswire.com published: “NetScientific appoints diagnostics leader Lawrence Cohen as CEO of Glycotest Inc.” on December 16, 2015. More interesting news about Netscientific PLC (LON:NSCI) was released by: Businesswire.com and their article: “NetScientific plc: Wandaâ„¢ Partners with Leading US Hospital Group Dignity …” with publication date: February 29, 2016.
NetScientific plc is a transatlantic healthcare technology company. The company has a market cap of 30.41 million GBP. The Firm develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in the United States and Europe with a primary focus on diagnostics, digital health and therapeutics. It currently has negative earnings. The Firm is engaged in the development of intellectual property.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.